Skip to content
    Clinical Trials

    STRIDE Plus Lenvatinib and TACE Improves Progression-Free Survival in Hepatocellular Carcinoma

    Kudo et alThe Lancet Oncology

    STRIDE Plus Lenvatinib and TACE Improves Progression-Free Survival in Hepatocellular Carcinoma
    The phase 3, global, randomised, open-label EMERALD-3 study evaluated durvalumab and tremelimumab (STRIDE) with or without lenvatinib combined with transarterial chemoembolisation (TACE) in patients with embolisation-eligible hepatocellular carcinoma (HCC). The combination of STRIDE, lenvatinib, and TACE achieved a statistically significant improvement in progression-free survival compared to TACE alone. These results support a STRIDE-based regimen as a potential new treatment strategy for this patient population, with additional clinical follow-up ongoing to evaluate final overall survival.

    Key Takeaways

    • STRIDE plus lenvatinib combined with transarterial chemoembolisation (TACE) demonstrated a statistically significant improvement in progression-free survival compared to TACE alone.
    • Findings support a STRIDE-based combination regimen as a potential new therapeutic option for embolisation-eligible hepatocellular carcinoma, with final overall survival analysis awaiting ongoing follow-up.
    Read the original sourceThe Lancet Oncology